LTS Lohmann Therapie-Systeme AG is the market leader in transdermal therapeutic systems. Founded in 1984, LTS has become a strong and innovative specialist medium-sized company. LTS develops and manufactures innovative drug delivery systems that offer the patient reliable therapeutic efficacy with the highest level of convenience and comfort with a proven track record on global markets.
Product innovations from LTS include e.g. the first nicotine patch and by the now widely known patches against Alzheimer's and Parkinson’s disease.
LTS pushes its development activities to new levels. In 2015, the first active TTS manufactured by LTS has been launched in the US. It is a patch which transports the active agent via iontophoresis (absorption of drugs through the skin due to an applied electric field) in the bloodstream.
LTS is further active in the development of microneedle – TTS. This technology will enable LTS in the future to offer a larger variety of TTS for additional therapeutic fields.
The LTS group has more than 1,200 employees in Germany and the US.